Senhwa Biosciences, Inc

Senhwa Biosciences, Inc., a clinical stage drug development company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer. Currently 2 main compounds CX-5461 and CX-4945 are both first- in- class small molecule drugs and ongoing phase I/II clinical trials in Australia, Canada, United States, Korea and Taiwan. Senhwas CX-5461 is a G-quadruplexes (G4) stabilizer, causing DNA damage of tumor cells through a synthetic lethality (SL) approach in patients with BRCA1/2 mutations or HR deficiency (HRD). Senhwas CX-4945 is a selective CK2 inhibitor and it has been shown to inhibit the phosphorylation of the DNA repair...

Targeted cancer therapy,first in class,dna damage response,synthetic lethality,orphan drug,multiple indications,rescue medication ,su2c-cbcf dream team drug,and precision medicine

Senhwa biosciences, inc operates in the Biotechnology industry.

Senhwa biosciences, inc's revenue is < 1m

Senhwa biosciences, inc has 11 - 50 employees.